OptimizeRx stock gets a higher USD 11.00 price target

OptimizeRx stock has a new USD 11.00 price target after B. Riley Securities maintained its Buy rating on September 29, 2026, according to MarketBeat. The target puts the analyst view above the USD 8.36 NASDAQ price available at 3:27 p.m. EDT on September 29, 2026.

B. Riley raises the target

According to MarketBeat, B. Riley Financial initiated coverage with a Buy rating and a USD 11.00 target. The report places the target above the USD 7.81 prior NASDAQ close cited in the same coverage, while OptimizeRx traded at USD 8.36 later on September 29, 2026.

The broader analyst picture is mixed but constructive. MarketBeat reported six Buy ratings, two Hold ratings and one Sell rating, producing a Moderate Buy consensus and a USD 11.57 average target.

Q2 revenue topped consensus

OptimizeRx reported Q2 2026 revenue of USD 20.50 million, exceeding the USD 20.20 million consensus estimate, while adjusted EPS reached USD 0.16 versus USD 0.11 expected. The figures were reported for the quarter ended June 30, 2026, in the company's results release carried by FinancialContent.

The comparison also shows the central tension in the latest results: earnings beat expectations, but the finance data show a USD 0.7 million net loss for Q2 2026. Operating cash flow was USD 8.6 million in the quarter, giving investors a second measure of performance beyond adjusted earnings.

Market value stays below yearly high

OptimizeRx had a market capitalization of USD 156.8 million on September 29, 2026. Its NASDAQ 52-week range was USD 4.54 to USD 22.25, leaving the latest USD 8.36 quote materially below the yearly high and closer to the lower end of the range.

At the September 29, 2026 snapshot, OptimizeRx was trading at EUR price data unavailable from a valid German venue quote, so the closing market reference is the company's USD 156.8 million market capitalization and its USD 4.54 to USD 22.25 NASDAQ 52-week range. The company operates in healthcare information services, providing digital messaging and engagement tools for life sciences companies, healthcare providers and patients.